Plexxikon

Plexxikon
Company typeSubsidiary
IndustryBiotechnology
Founded2001 (2001)
FounderJoseph Schlessinger
Defunct2011; 13 years ago (2011)
FateAcquired by the Daiichi Sankyo
HeadquartersSouth San Francisco, California, United States.
Websitewww.plexxikon.com Edit this on Wikidata

Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.

It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.[citation needed][1]

In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[2][3][4]

Daiichi Sankyo announced the shutdown of Plexxikon in 2022.[5]

  1. ^ "AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry". www.biopharmatrend.com. Retrieved 2023-09-11.
  2. ^ "Daiichi Sankyo to Acquire Plexxikon". Plexxikon. 2011-02-28. Archived from the original on 2011-03-06.
  3. ^ "Plexxikon acquired by Daiichi Sankyo". Haberman Associates. 2011-03-03. Retrieved 2020-08-06.
  4. ^ "Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition". BioSpace. Retrieved 2020-08-06.
  5. ^ Wells, Madeline (2022-01-12). "South SF company bought for $800 million is being shut down". SFGATE. Archived from the original on 2022-01-12.